---
document_datetime: 2023-09-21 21:10:46
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zynteglo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: zynteglo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.2430887
conversion_datetime: 2025-12-14 20:35:25.886643
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Zynteglo

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                   | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                           |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|------------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/10769 /202105  | Periodic Safety Update EU Single assessment - betibeglogene autotemcel                                                                                                                                  | 13/01/2022                                  | n/a                                            |                                  | PRAC Recommendation - maintenance |
| IB/0029              | B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method Medicinal | 10/12/2021                                  | n/a                                            |                                  |                                   |

<!-- image -->

Medicinal product no longer authorised

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

| N/0030   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 09/12/2021         | 22/03/2022              | PL                 |                                                                                |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------------------|--------------------|--------------------------------------------------------------------------------|
| IB/0028  | B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 29/09/2021         | n/a                     | authorised         |                                                                                |
| II/0025  | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 16/09/2021         | n/a                     |                    |                                                                                |
| A20/0023 | Pursuant to Article 20 of Regulation (EC) No 726/2004 the European Commission requested on 18 February 2021 the opinion of the European Medicines Agency further to concerns regarding a possible causal association between the lentiviral vector or other aspects related to the therapy and the onset of AML/MDS in patients receiving a medicinal product for treatment of sickle cell disease containing the same lentiviral vector as Zynteglo. On 18 February 2021 the CHMP was requested to assess the impact thereof on the benefit-risk balance of Zynteglo and to give its recommendation whether the marketing authorisation of this product should be maintained, varied, suspended or revoked. As the request results from the evaluation of data resulting from pharmacovigilance activities, the CHMP opinion was adopted on the basis of a recommendation of the Pharmacovigilance Risk Assessment Committee. Medicinal | 22/07/2021 product | 16/09/2021 II no longer | SmPC, Annex and PL | Please refer to the assessment report: Zynteglo EMEA/H/A-20/1504/C/003691/0023 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| R/0018              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22/07/2021   | 16/09/2021            | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Zynteglo, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. authorised   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0026/G           | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient Medicinal | 11/09/2021   | n/a product no longer |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| PSUSA/10769 /202011 | Periodic Safety Update EU Single assessment - betibeglogene autotemcel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 08/07/2021   | n/a                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0022             | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                                                                           | 20/05/2021         | n/a                 |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|---------------------|-----------------------------------|
| IB/0024             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                 | 03/05/2021         | n/a                 | authorised                        |
| PSUSA/10769 /202005 | Periodic Safety Update EU Single assessment - betibeglogene autotemcel                                                                                                                                                                                                                                                                                               | 14/01/2021         | n/a longer          | PRAC Recommendation - maintenance |
| N/0020              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                     | 18/12/2020         | 09/07/2021 PL       |                                   |
| II/0017             | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                               | 10/12/2020 product | n/a no              |                                   |
| IAIN/0019/G         | This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name Medicinal | 01/12/2020         | 09/07/2021 Annex PL |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | or supplier of the AS, starting material, intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test   | reagent or product no longer   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| IB/0016   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure 04/11/2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | n/a                            |
| IA/0015/G | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) 28/08/2020 Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | n/a                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information   |                      |               |                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|---------------|-----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10769 /201911 | Periodic Safety Update EU Single assessment - betibeglogene autotemcel                                                                                                           | 09/07/2020           | n/a           |                                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0013             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                    | 08/07/2020           | 09/07/2021    | Annex II and Labelling authorised |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0012             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place       | 06/07/2020           | n/a no longer |                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0011             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data           | 29/05/2020 product   | n/a           |                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| R/0005              | Renewal of the marketing authorisation.                                                                                                                                          | 27/02/2020 Medicinal | 28/04/2020    | SmPC, Annex II and PL             | The CAT/CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Zynteglo, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IA/0008   | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                  | 21/02/2020         | n/a        |                                  |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------|----------------------------------|
| IB/0009   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                | 20/02/2020         | n/a        |                                  |
| IB/0007   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                  | 03/02/2020         | n/a        | authorised                       |
| IB/0006   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                  | 20/12/2019         | n/a no     | longer                           |
| IB/0004/G | This was an application for a group of variations. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data Medicinal | 18/12/2019 product | n/a        |                                  |
| IB/0003   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                               | 31/10/2019         | 28/04/2020 | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0001/G   | This was an application for a group of variations. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits   | 17/10/2019   | n/a authorised   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------------|
| IB/0002     | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                     | 30/08/2019   | n/a no longer    |